NetherRealm has published the first gameplay for Mortal Kombat 1 DLC guest fighter the T-1000. The T-1000 teaser trailer, which is viewable below, includes a look at one of the character’s fatalities, ...

Terminator's T-1000 is coming to Mortal Kombat 1 next month ... Homelander (The Boys), and Takeda Takahashi. T-1000, however, is coming as part of Kombat Pack 2, alongside Scream's Ghostface ...

These are all the Diamond cards currently released in Mortal Kombat Mobile. Some of them depend on the team ... Sonya Blade (Klassic), Sonya Blade (Kombat Cup), Sub-Zero (Klassic), Takeda (Shirai Ryu) ...

Takeda has returned to BridGene Biosciences for another small-molecule collaboration—this time focused on immunology as well as neurology. BridGene’s pursuit of undruggable targets is enabled ...

Takeda’s (NYSE: TAK) (TSE:4502) plasma-derived therapies (PDT) business, led by Giles Platford, president of Takeda’s Plasma-Derived Therapies Business Unit and chair of the Plasma Protein ...

The Mortal Kombat 1 Kombat Pack grants access to 11 DLC characters, but the release dates for these MK1 kombatants are all a ...

Takeda's long-serving chief executive Christophe Weber has said he will retire next year, after 12 years at the Japanese drugmaker. Weber – who was briefly chief operating officer of Takeda ...

On Monday, Protagonist Therapeutics, Inc. (NASDAQ:PTGX) and Takeda Pharmaceutical Co Ltd (NYSE:TAK) released topline results for the Phase 3 VERIFY study of rusfertide for polycythemia vera.

In this article, we are going to take a look at where Takeda Pharmaceutical Company Limited (NYSE:TAK) stands against the other Japanese stocks. As the dangers of natural disasters increase and ...

January 30, 2025 Drugmaker Takeda's CEO Weber to step down, raises profit forecast Takeda Pharmaceutical said on Thursday its CEO Christophe Weber will retire after more than a decade at the helm ...

Takeda has bolstered its near-term pipeline in rare haematological disorders by licensing rights to a polycythaemia vera (PV) treatment being developed by Protagonist Therapeutics. The Japanese ...